Country: Canada
Language: English
Source: Health Canada
AMOXICILLIN (AMOXICILLIN TRIHYDRATE)
PHARMASCIENCE INC
J01CA04
AMOXICILLIN
250MG
CAPSULE
AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 250MG
ORAL
500/1000
Prescription
AMINOPENICILLINS
Active ingredient group (AIG) number: 0131314001; AHFS:
APPROVED
1996-12-19
PRODUCT MONOGRAPH PR PMS-AMOXICILLIN Amoxicillin Capsules 250 mg and 500 mg amoxicillin (as amoxicillin trihydrate) Amoxicillin Granules for Oral Suspension 125 mg/5 mL and 250 mg/5 mL amoxicillin (as amoxicillin trihydrate) after reconstitution USP Standard ANTIBIOTIC PHARMASCIENCE INC. DATE OF REVISION: 6111 Ave. Royalmount Avenue, Suite #100 October 30, 2020 Montréal, Québec H4P 2T4 www.pharmascience.com Submission Control No.: 243965 _ pms-AMOXICILLIN Product Monograph _ _Page 2 of 24_ NAME OF DRUG PR PMS-AMOXICILLIN Amoxicillin Capsules, USP Amoxicillin Granules for Oral Suspension, USP THERAPEUTIC CLASSIFICATION Antibiotic ACTION AND CLINICAL PHARMACOLOGY pms-AMOXICILLIN (amoxicillin) exerts its bactericidal action by interfering with bacterial cell wall synthesis. INDICATIONS AND CLINICAL USE pms-AMOXICILLIN (amoxicillin) may be indicated in the treatment of infections due to susceptible strains of the following micro-organisms: Gram-negative organisms: H. influenzae, P. mirabilis and N. gonorrhoeae. Gram-positive organisms: Streptococci (including Streptococcus faecalis and Streptococcus pneumoniae). Amoxicillin is not active against Pseudomonas aeruginosa, indole-positive Proteus species, Serratia marcescens, Klebsiella and Enterobacter species. In emergency cases, where the causative organism is not yet identified, therapy may be initiated with amoxicillin on the basis of clinical judgment while awaiting bacteriologic tests to determine its antimicrobial sensitivity. pms-AMOXICILLIN may be indicated as a prophylaxis against alpha-hemolytic (Viridan's group) Streptococci before dental, oral or upper respiratory tract surgery or instrumentation. It may be also indicated as a prophylaxis of bacterial endocarditis in patients with any of the following conditions: congenital cardiac malformations, rheumatic and other acquired valvular lesions, prosthetic heart valves, previous history of bacterial endocarditis, hypertrophic cardiomyopathy, surgically constructed systemic pulmonary shunts, mitral valve prol Read the complete document